Non-Small Cell Lung Cancer - Metastatic

Correlatives

IRB#9059
Lung Cancer Mutation Consortium

1st line

Squamous

IRB# 11851
GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) In Combination With Carboplatin+Paclitaxel Or Atezolizumab In Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel In Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

Non-squamous

IRB# 11845
GO29431: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) Compared with a Platinum Agent (Cisplatin or Carboplatin) in Combination with Either Pemetrexed orGemcitabine for PD-L1-Selected Chemotherapy Naive Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

2nd/3rd Line

IRB#11740
Tiger 3: Rociletinib Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR

IRB#11046
Lung-MAP: Study involving multiple drugs

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/os/knight.php

1/23/2017